French premier Alain Juppe has indicated that his social security reform plan will go ahead in 1996, apart from some proposals on special retirement regimes which were abandoned during the nationwide strikes.
Parliamentary examination of plans to revise the constitution to give parliament more control over social spending will start at end-January, while the new rules on the control of health care spending in general practice, health fund and other social security management and the reform of the hospitals sector will be worked out by end-April. A draft law setting up a universal health insurance regime is among other reform projects due for completion before the summer.
Last month French doctors demonstrated on the streets of Paris, for the first time in four years, against one of the main themes of the reform, a 1996 limit on medical spending of 2.1%. The protest was supported by the CSMF, SML and FMF doctors' organizations, but not by MG France, to which most general practitioners belong, which refused because talks were underway with the government. Nor was it backed by the surgeons in the UCCSF, which said the Juppe plan was "the first serious and courageous attempt to inject order into the social protection system."
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze